DAWN Stock Price, Day One Biopharmaceuticals, . Quote, Chart

Market Summary

USD16.05+0.05

Market Closed

0.31%

DAWN Alerts

3 major insider sales recently.

DAWN Stock Price

View Fullscreen

DAWN RSI Chart

DAWN Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-6.71

Price/Sales (Trailing)

77.55

Price/Free Cashflow

-8.21

DAWN Price/Sales (Trailing)

DAWN Profitability

Return on Equity

-70.39%

Return on Assets

-63.96%

Free Cashflow Yield

-12.18%

DAWN Fundamentals

DAWN Revenue

Revenue (TTM)

18.1M

Rev. Growth (Yr)

25.94%

Rev. Growth (Qtr)

-13.12%

DAWN Earnings

Earnings (TTM)

-208.9M

Earnings Growth (Yr)

-47.22%

Earnings Growth (Qtr)

-14.49%

Breaking Down DAWN Revenue

Last 7 days

-3.3%

Last 30 days

16.6%

Last 90 days

13.1%

Trailing 12 Months

20.7%

How does DAWN drawdown profile look like?

DAWN Financial Health

Current Ratio

10.93

DAWN Investor Care

Shares Dilution (1Y)

18.78%

Diluted EPS (TTM)

-2.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	18.1M	0	0	0
2023	8.2M	11.4M	14.8M	17.2M
2022	0	0	0	4.7M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Day One Biopharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	bender jeremy	sold	-163,417	17.852	-9,154	chief executive officer
May 03, 2024	york charles n ii	sold	-144,214	17.8527	-8,078	coo, cfo and secretary
May 02, 2024	bender jeremy	sold	-107	17.9375	-6.00	chief executive officer
May 02, 2024	york charles n ii	sold	-3,579	17.8955	-200	coo, cfo and secretary
May 01, 2024	york charles n ii	sold	-933,397	17.887	-52,183	coo, cfo and secretary
May 01, 2024	bender jeremy	sold	-1,252,180	17.8753	-70,051	chief executive officer
Apr 18, 2024	blackman samuel c.	sold	-160,163	16.0163	-10,000	head of r&d
Mar 25, 2024	blackman samuel c.	sold	-160,055	16.0055	-10,000	head of r&d
Mar 11, 2024	blackman samuel c.	sold	-457,314	15.2438	-30,000	head of r&d
Feb 27, 2024	blackman samuel c.	sold	-322,166	16.1083	-20,000	head of r&d

Which funds bought or sold DAWN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	BlackRock Inc.	reduced	-1.85	8,278,670	83,119,300	-%
May 10, 2024	VANGUARD GROUP INC	added	0.1	9,236,170	78,874,500	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	26.18	4,856,760	16,215,600	-%
May 10, 2024	Vontobel Holding Ltd.	sold off	-100	-226,300	-	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	14,901	14,901	-%
May 10, 2024	GROUP ONE TRADING, L.P.	new	-	82,683	82,683	-%
May 10, 2024	PNC FINANCIAL SERVICES GROUP, INC.	sold off	-100	-891	-	-%
May 10, 2024	JUPITER ASSET MANAGEMENT LTD	sold off	-100	-535,397	-	-%
May 10, 2024	CITIGROUP INC	added	71.18	1,366,840	2,825,750	-%
May 10, 2024	Covestor Ltd	reduced	-12.5	-	-	-%

Are Funds Buying or Selling DAWN?

Are funds buying DAWN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DAWN

No. of Funds

DAWN Alerts

3 major insider sales recently.

Unveiling Day One Biopharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.0%	7,809,852	SC 13G/A
Feb 13, 2024	vanguard group inc	5.48%	4,769,746	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	atlas venture fund xi, l.p.	6.9%	6,008,534	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	5,126,071	SC 13G
Oct 20, 2023	ai day1 llc	14.87%	12,929,322	SC 13D/A
Aug 10, 2023	fmr llc	-	0	SC 13G/A
Jun 12, 2023	ai day1 llc	13.19%	11,453,868	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	9.6%	7,040,622	SC 13G/A
Feb 14, 2023	atlas venture fund xi, l.p.	8.2%	6,008,534	SC 13G/A

Recent SEC filings of Day One Biopharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	144	Notice of Insider Sale Intent
Apr 24, 2024	8-K	Current Report
Apr 22, 2024	4	Insider Trading
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Day One Biopharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Day One Biopharmaceuticals, Inc. News

Latest updates

Day One Biopharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-13.1%	4,365	5,024	5,291	3,406	3,466	2,660	1,895	189	-	-
Operating Expenses	12.2%	66,767	59,517	51,438	49,254	45,855	42,743	39,699	36,719	27,748	21,976
S&GA Expenses	-100.0%	-	22,169	18,275	17,072	18,027	16,723	17,664	14,159	12,745	10,787
R&D Expenses	7.7%	40,210	37,348	33,163	32,182	27,828	26,020	22,035	22,560	15,003	11,189
Interest Expenses	-	-	-	-	-	-	2,660	1,895	189	2.00	24.00
Net Income	-14.5%	-62,412	-54,511	-46,150	-45,863	-42,393	-40,109	-37,795	-36,530	-27,747	-22,993
Net Income Margin	-5.1%	-11.55*	-10.99*	-11.77*	-14.54*	-19.10*	-29.96*	-	-	-	-
Free Cashflow	-20.2%	-49,729	-41,380	-37,105	-42,581	-26,011	-35,310	-23,218	-29,794	-21,578	-13,169

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-13.1%	327	376	414	451	324	349	382	404	268	290	304	317	46.00
Current Assets	-13.1%	326	375	413	450	-	348	-	-	-	289	-	-	45.00
Cash Equivalents	17.2%	270	231	241	189	49.00	85.00	121	389	263	284	297	310	44.00
Net PPE	-11.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	1.1%	30.00	30.00	25.00	25.00	23.00	17.00	19.00	13.00	8.00	9.00	6.00	5.00	2.00
Current Liabilities	1.1%	30.00	30.00	24.00	25.00	23.00	17.00	18.00	13.00	8.00	9.00	6.00	5.00	2.00
Shareholder's Equity	-14.4%	297	347	390	426	300	332	363	391	260	281	298	312	-
Retained Earnings	-13.6%	-521	-458	-404	-357	-312	-269	-229	-191	-155	-127	-105	-86.31	-56.84
Additional Paid-In Capital	1.6%	818	805	794	784	612	602	593	582	415	409	403	398	-
Shares Outstanding	0.2%	87.00	87.00	87.00	87.00	74.00	73.00	64.00	60.00	58.00	37.00	30.00	23.00	-
Float	-	-	-	-	759	-	-	-	698	-	-	-	646	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-20.2%	-49,729	-41,372	-37,064	-42,432	-25,985	-35,310	-23,214	-29,787	-21,563	-13,169	-12,221	-13,406	-9,743	-5,938	-3,578	-	-
Share Based Compensation	-100.0%	-	10,811	9,606	9,477	9,447	6,833	8,576	5,631	6,202	5,097	5,149	2,537	538	350	60.00	57.00	-
Cashflow From Investing	193.9%	89,288	30,380	88,917	20,274	-11,193	-2,210	-246,852	-5,997	-15.00	-	-	-	-8,000	1.00	-	-	-
Cashflow From Financing	-92.0%	48.00	597	115	162,101	1,184	1,918	2,053	161,930	-	318	-615	168,532	128,885	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DAWN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 40,210	$ 27,828
General and administrative	26,557	18,027
Total operating expenses	66,767	45,855
Loss from operations	(66,767)	(45,855)
Investment income, net	4,365	3,466
Other expense, net	(10)	(4)
Net loss attributable to common stockholders	$ (62,412)	$ (42,393)
Net loss per share, basic	$ (0.72)	$ (0.59)
Net loss per share, diluted	$ (0.72)	$ (0.59)
Weighted-average number of common shares used in computing net loss per share, basic	86,679,282	71,972,888
Weighted-average number of common shares used in computing net loss per share, diluted	86,679,282	71,972,888

DAWN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 270,391	$ 230,784
Short-term investments	47,553	135,563
Prepaid expenses and other current assets	8,090	8,927
Total current assets	326,034	375,274
Property and equipment, net	185	208
Operating lease right-of-use asset	259	352
Deposits and other long-term assets	167	214
Total assets	326,645	376,048
Current Liabilities:
Accounts payable	4,780	2,576
Accrued expenses and other current liabilities	24,759	26,524
Current portion of operating lease liabilities	300	408
Total current liabilities	29,839	29,508
Total liabilities	29,839	29,508
Commitments and contingencies (Note 6)
Stockholders' equity
Common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 87,377,163 and 87,227,132 shares issued and outstanding as of Mach 31, 2024 and December 31, 2023, respectively	9	9
Additional paid-in-capital	817,799	805,107
Accumulated other comprehensive loss	(5)	9
Accumulated deficit	(520,997)	(458,585)
Total stockholders' equity	296,806	346,540
Total liabilities and stockholders' equity	$ 326,645	$ 376,048

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

CEO	Dr. Jeremy Bender M.B.A., Ph.D.
WEBSITE	https://dayonebio.com
INDUSTRY	Biotechnology
EMPLOYEES	124

Day One Biopharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Day One Biopharmaceuticals, Inc.? What does DAWN stand for in stocks?

DAWN is the stock ticker symbol of Day One Biopharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Day One Biopharmaceuticals, Inc. (DAWN)?

As of Mon May 13 2024, market cap of Day One Biopharmaceuticals, Inc. is 1.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DAWN stock?

You can check DAWN's fair value in chart for subscribers.

What is the fair value of DAWN stock?

You can check DAWN's fair value in chart for subscribers. The fair value of Day One Biopharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Day One Biopharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DAWN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Day One Biopharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether DAWN is over valued or under valued. Whether Day One Biopharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Day One Biopharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DAWN.

What is Day One Biopharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, DAWN's PE ratio (Price to Earnings) is -6.71 and Price to Sales (PS) ratio is 77.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DAWN PE ratio will change depending on the future growth rate expectations of investors.